Divamics Secures Tens of Millions in Series A Funding to Advance Nucleic Acid Therapeutics and Protein Degraders

Recently,Divamics Inc. (hereinafter referred to as "Divamics")Completed tens of millions of yuan in Series A financing. This round of financing was led byYuSheng Venture CapitalLed the investment. The funds raised will be used to accelerate the iteration and upgrading of the technology platform and expand the global drug cooperation pipeline.

Divamics, established in 2021, is committed to building an "innovation crucible" for new drug development. Through its proprietary "Molecular Movie" algorithm and early-stage drug discovery decision-making platform, it efficiently drives innovation in new drug development. Its core technology and platform significantly reduce the preclinical trial-and-error costs of new drug research, while increasing speed and success rates.

As a "technical dark horse" in the AIDD (AI Drug Discovery and Design) field, Divamics"Multi-scale Molecular Dynamics + AI Algorithm"The deep integration has already taken place inProtein Degraders, GPCR Targets, Nucleic Acid DrugsBuild differentiated competitiveness in cutting-edge fields. Its core technology system breaks through the limitations of traditional static structure prediction by simulating the dynamic conformational changes of biomolecules (such as protein flexibility, induced fit upon ligand binding), providing atomic-level mechanistic insights for drug design.

Notably, the company has recently achieved multiple breakthroughs in technology research and development, commercial cooperation, and other aspects.

Technically,Divamics' Self-Developed First-Generation AI Drug Design Algorithm Officially Granted U.S. Patent.The algorithm employs deep learning to model fingerprint profiles for each atom type in drug and target molecules. It is highly interpretable, excels at uncovering unknown mechanisms at the molecular level, easily discovers new conformations and binding pockets of allosteric drugs, and enables rational design based on macromolecular flexibility. It is suitable for drug discovery across different modalities.

Building on this breakthrough,Divamics further completes the framework construction of the world's first kinetic trajectory database.Integrate big data related to drug development, uncover the underlying molecular mechanisms behind the pharmacodynamics and pharmacology of different pipelines, efficiently analyze clinical and patent information, and make precise decisions in the logical chain of new drug development. It reshapes the innovative chain from molecular discovery to clinical validation, ensuring that drug molecules possess inherent clinical efficacy potential.

In February this year,Divamics, in collaboration with top research teams from Peking University School of Pharmaceutical Sciences and Wuhan University of Technology, published their research成果《Systematic evolution of functional oligonucleotides for targeted protein degradation》online in the journal《Chem》(a Cell subsidiary)., providing strong support for the development of novel protein degraders.

In terms of commercialization, Divamics' dual-driven strategy of "deep cultivation in the local market + global expansion" has achieved remarkable results. In the Chinese market,Two drug pipelines合作的两条药物管线

In the international market, since the launch of the overseas strategy in the second half of 2024,Divamics Rapidly Expands Overseas Markets, with Overseas Revenue Now Exceeding 60% of the Company's Total Income. Particularly, Since Last Year’s Strategic Cooperation with a Leading North American Pharma Company, the Two Parties Have Initiated Collaboration on 16 Drug Pipelines According to the Contract Terms, and Have Successfully Delivered 2 Projects.

With the deepening of international cooperation, the company has further broken through business boundaries,Signed the first "full-package dry and wet lab" order with overseas clients by the end of 2024.By integrating the full-chain capabilities of AI design, dynamic simulation, and experimental validation, it has officially entered a new phase as an integrated solutions provider.

To date, Divamics has established extensive collaborations with more than 50 global clients, participating in over 80 drug discovery pipelines and projects.

For securing this round of financing,Founder of Divamics, Zheng ZhenDivamics Expresses: Divamics is highly honored to collaborate with OrbiMed China. This round of investment and financing cooperation is also based on the high degree of industrial alignment and synergy between both parties. Divamics is committed to enhancing the R&D efficiency of innovative drugs. Our unique technical approach deeply integrates AI with physical simulations, aiming for a more precise understanding of the dynamic interactions and mechanisms between drug molecules and targets, enabling rational drug design, efficacy prediction, and drug-likeness assessment, thereby breaking through traditional bottlenecks in drug discovery. Over the past three years, we have continuously iterated and upgraded our core platform, achieving positive results through collaboration with dozens of global enterprises, validating the technical feasibility and potential, and demonstrating a clear value proposition and growth prospects. This round of financing marks further market recognition of the company’s technical strength, business model, and team execution capabilities, as the company has entered a more mature stage of value creation. Leveraging this round of financing, we will further expand the types of targets and drug modalities that our platform can handle, and establish an operational management system necessary to support global strategic partnerships. All members of Divamics will continue to fully commit themselves, driving profound transformation in the pharmaceutical industry through continuous innovation and open collaboration, ultimately benefiting patients worldwide.

Dr. Cheng Gang, Partner of YuanSheng VenturesRepresents: Based on molecular dynamics models, the company integrates the latest machine learning and AI technologies to achieve a reasonable balance between simulation accuracy and speed for drug molecule design and optimization. It is applicable to various molecular types, including small molecules, peptides, antibodies, etc., with the potential to greatly enhance the efficiency of early-stage drug molecule development. Against the backdrop of strong national support for AI-related industries in China, Divamics...The work aligns closely with this direction, effectively empowering pharmaceutical R&D companies both in China and internationally. YuanSheng Ventures looks forward to supporting Divamics in its continuous innovation and rapid development, becoming a leading company in the AI-assisted pharmaceutical field within China and even globally.

OrbiMed China is a venture capital firm focusing on early-stage and growth-stage investments in the healthcare sector. Headquartered at BioBAY in Suzhou, it has a global reach. To date, it has invested in over 200 outstanding companies in the life sciences sector, spanning four key areas: novel drug discovery, medical devices, in vitro diagnostics and precision medicine, as well as future medical technologies. These investments have yielded substantial returns, with 19 portfolio companies going public on capital markets such as the Hong Kong Stock Exchange and STAR Market. OrbiMed China has been repeatedly ranked among the top 10 venture capital funds in China's healthcare sector and recognized as one of the most active healthcare investment firms in the country. With a team of seasoned professional investors and a world-class scientific advisory board, OrbiMed China boasts extensive experience in entrepreneurship, venture capital, and corporate operations within the biopharmaceutical industry. Leveraging its expertise, focus, and wealth of industry resources, the firm aspires to become one of the most successful healthcare and pharmaceutical venture capital funds in China.